Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Robert H. Lurie Cancer Center
- Registration Number
- NCT00004903
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00003081
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003899
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003146
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Conditions
- Interventions
- Drug: melphalanProcedure: autologous hematopoietic stem cell transplantationProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiationDrug: cyclosporineDrug: mycophenolate mofetilBiological: therapeutic allogeneic lymphocytes
- First Posted Date
- 2004-04-15
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00003954
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003080
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 68
- Registration Number
- NCT00080886
- Locations
- 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 35
- Registration Number
- NCT00003402
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00002601
- Locations
- 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Medsearch
- Registration Number
- NCT00014339
- Locations
- 🇺🇸
Southwest Cancer Care, Poway, California, United States
🇺🇸West Clinic, P.C., Memphis, Tennessee, United States
🇺🇸Oncology-Hematology Associates, P.A., Clinton, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.